|
|
Home | Pain Overview | Types of Pain | Treatment Methods | Chiropractors | Anesthesiologists | Biofeedback | Videos | Get Answers To All Of Your Pain Questions Massage | Pain Management Drugs | Glossary of Pain Drugs | Top Pain Programs | Pain Associations | Pain Doctors | Pain Terminology | Insurance | Site Map
(Cox-2 inhibitors) Summary of COX-2 inhibitors are a type of nonsteroidal anti-inflammatory drug (NSAID) that specifically inhibits an enzyme known as cyclooxygenase-2 (COX-2). These drugs are used to treat pain and may be less likely to cause gastrointestinal bleeding than other NSAIDs. Cyclooxygenase comes in two forms: COX-1 and COX-2. Unlike other NSAIDs, COX-2 inhibitors suppress only one form of cyclooxygenase, COX-2. Researchers believe part of the role of COX-1 is to protect your stomach lining. Because the other NSAIDs suppress its function, side effects such as stomach and bleeding problems can result. COX-2 inhibitors affect only that form of the enzyme (COX-2) involved in inflammation. Because they don't affect COX-1, COX-2 inhibitors may cause fewer side effects in your digestive system. However, this result, along with the long-term effects of COX-2 inhibitors, needs to be verified with further research. In addition, COX-2 inhibitors don't thin your blood like aspirin and other NSAIDs. If your doctor has prescribed aspirin for a heart condition, don't use COX-2 inhibitors instead.
Celecoxib is a non-steroidal anti-inflammatory drug (NSAID) used in the treatment of osteoarthritis, rheumatoid arthritis, acute pain, painful menstruation and menstrual symptoms, and to reduce numbers of colon and rectum polyps in patients with familial adenomatous polyposis. It is marketed by Pfizer under the brand name Celebrex. In some countries, it is branded Celebra. Celecoxib is available by prescription in capsule form. Celecoxib is licensed for use in osteoarthritis, rheumatoid arthritis, acute pain, painful menstruation and menstrual symptoms, and to reduce the number of colon and rectal polyps in patients with familial adenomatous polyposis. It was originally intended to relieve pain while minimizing the gastrointestinal adverse effects usually seen with conventional NSAIDs. In practice, its primary indication is in patients who need regular and long term pain relief: there is probably no advantage to using celecoxib for short term or acute pain relief over conventional NSAIDs. In particular, the pain relief offered by celecoxib is similar to that offered by paracetamol. The usual adult dose of celecoxib is 100 to 200mg once or twice a day. The lowest effective dose should be used. After the withdrawal of rofecoxib (Vioxx) from the market in September 2004, Celebrex enjoyed a robust increase in sales. However, the results of the APC trial in December of that year raised concerns that Celebrex might carry risks similar to those of Vioxx, and Pfizer announced a moratorium on direct-to-consumer advertising of Celebrex soon afterwards. After a significant drop, sales of Celebrex have recovered, and reached $2 billion in 2006.Pfizer resumed advertising Celebrex in magazines in 2006, and resumed television advertising in April of 2007 with an unorthodox, 2.5 minute advertisement which extensively discussed the adverse effects of Celebrex in comparison to other anti-inflammatory drugs. The ad drew criticism from the consumer advocacy group Public Citizen, which called the ad's comparisons misleading.
Source: Marketdata Enterprises, Inc., Chronic Pain Management Programs: A Market Analysis, Wikipedia, various other sources
|
|
||||
|
||||||
